ExodusPoint Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

ExodusPoint Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-155,020	Closed	-$313K	–	2702
2022 Q1	$313K	Buy	155,020 +82,152	+113%	+$161K	﹤0.01%	1742
2021 Q4	$197K	Sell	72,868 -7,334	-9%	-$27.1K	﹤0.01%	1835
2021 Q3	$358K	Sell	80,202 -37,877	-32%	-$182K	﹤0.01%	1550
2021 Q2	$685K	Buy	+118,079	New	+$692K	0.01%	1200
2020 Q4	–	Sell	-33,169	Closed	-$193K	–	2517
2020 Q3	$193K	Sell	33,169 -5,393	-14%	-$32.3K	﹤0.01%	1492
2020 Q2	$260K	Buy	+38,562	New	+$292K	0.01%	1386
2020 Q1	–	Sell	-12,415	Closed	-$129K	–	1801
2019 Q4	$129K	Buy	+12,415	New	+$90.3K	﹤0.01%	1401

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

ExodusPoint Capital Management's CLVS Position: Q2 2022 in Review

ExodusPoint Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q2 2022, closing a stake of 155,020 shares — an estimated $313K sold.

ExodusPoint Capital Management first reported a position in CLVS in Q4 2019 and held it in 7 quarters. The position peaked at $685K in Q2 2021. 115 funds tracked by Wall St. Rank hold CLVS as of Q2 2022.

ExodusPoint Capital Management reported no remaining Clovis Oncology, Inc. position as of Q2 2022 after selling out during the quarter.
ExodusPoint Capital Management sold 155,020 Clovis Oncology, Inc. shares in Q2 2022, an estimated $313K.
ExodusPoint Capital Management first reported a position in Clovis Oncology, Inc. in Q4 2019 and held it in 7 quarters.
ExodusPoint Capital Management's Clovis Oncology, Inc. position peaked at $685K in Q2 2021.
115 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.